AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma

Rupesh Paudel(Universitätsklinikum Würzburg), Marc Schmidt(Universitätsklinikum Würzburg), Katharina Meder(Universitätsklinikum Würzburg), M-E Goebeler(Universitätsklinikum Würzburg), Simon Goller(Universitätsklinikum Würzburg), Stefanie Schwarz(Universitätsklinikum Würzburg)
Neoplasia
March 31, 2026
10.1016/j.neo.2026.101301
Cited by 0

Related Papers

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
|Leukemia|2017|339
How Does the Eye Breathe?
|Journal of Biological Chemistry|2003|314
Neuroglobin and cytoglobin in search of their role in the vertebrate globin family
|Journal of Inorganic Biochemistry|2004|298
Cytoglobin Is a Respiratory Protein in Connective Tissue and Neurons, Which Is Up-regulated by Hypoxia
|Journal of Biological Chemistry|2004|222
The MEK5/ERK5 Pathway in Health and Disease
|International Journal of Molecular Sciences|2021|78